The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRBS.L Regulatory News (RBS)

  • There is currently no data for RBS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Disposal of shareholdings in Euroclear plc

24 Oct 2017 17:37

RNS Number : 5129U
Royal Bank of Scotland Group PLC
24 October 2017
 

Royal Bank of Scotland Group PLC

24 October 2017

 

Disposal of shareholdings in Euroclear plc

 

The Royal Bank of Scotland Group plc ("RBS") announces that its subsidiaries have today entered into an agreement to dispose of RBS' entire shareholdings in Euroclear plc to IntercontinentalExchange Holdings.

 

The transaction, which was also completed today, involved the sale of 148,349 ordinary shares in Euroclear plc for a total cash consideration of €275 million (approximately £245 million at current exchange rates)*. KPMG Corporate Finance acted as financial advisers to RBS and Simmons & Simmons acted as legal advisers to RBS on this transaction.

 

The sale proceeds will be used for general corporate purposes. The transaction is part of the continued reduction of assets in RBS and is in line with the bank's plan to strengthen its capital position.The carrying value of the shareholding in Euroclear plc as at 30 June 2017 was approximately £88 million, which represents RWA equivalent of around £220 million. The transaction is expected to generate a gain of approximately £175 million after associated costs, reserves recycling and before tax, which will be recognised as a gain on strategic disposal in Q4 2017.

 

For further information, please contact:

RBS Investor RelationsMatt WaymarkHead of Investor RelationsTel: +44 (0) 20 7672 1758

 * Under the terms of the sale agreement, additional consideration may become payable in certain circumstances if the purchaser either resells Euroclear plc shares acquired pursuant to this transaction or acquires further shares in Euroclear plc, in each case at or above certain agreed pricing thresholds within a specified period following completion.

FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, including (but not limited to) those with respect to RBS and its subsidiaries' regulatory capital position, financial position, risk-weighted assets, profitability and financial performance and the implementation of RBS's transformation programme under certain specified scenarios. In addition, forward-looking statements may include, without limitation, statements containing words such as "intends", "believes", "expects", "anticipates", "targets", "plans", "will" and similar expressions or variations on these expressions. These statements concern or may affect future matters, such as RBS's future economic results, business and capital plans and ability to achieve current strategies. Forward-looking statements are subject to a number of risks and uncertainties that might cause actual results and performance to differ materially from any expected future results or performance expressed in, or implied by, the forward-looking statements. Factors that could cause or contribute to differences in current expectations include, but are not limited to, legislative, political, fiscal and regulatory developments, accounting standards, competitive conditions, technological developments, interest and exchange rate fluctuations and general economic conditions. These and other factors, risks and uncertainties that may impact any forward-looking statement or RBS's actual results are discussed in RBS's 2016 Annual Report and Accounts (ARA) and its interim results for the six-months ended 30 June 2017 and materials filed with, or furnished to, the United States Securities and Exchange Commission, including, but not limited to, RBS's most recent Annual Report on Form 20-F and Reports on Form 6-K. The forward-looking statements contained in this announcement speak only as of the date they are made or revised and RBS does not assume or undertake any obligation or responsibility to update any of the forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.

Legal Entity Identifier: 2138005O9XJIJN4JPN90, RR3QWICWWIPCS8A4S074

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISMIBFTMBTTBFR
Date   Source Headline
17th Mar 20205:24 pmRNSDirectorate Change
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn
17th Mar 20204:38 pmRNSPrice Monitoring Extension
17th Mar 20208:30 amRNSMorgan Stanley European Financials Conference
16th Mar 20205:14 pmRNSNatWest Markets N.V. 2019 ARA
10th Mar 20204:51 pmRNSDirector/PDMR Shareholding
2nd Mar 20202:34 pmRNSDirector/PDMR Shareholding
28th Feb 20204:29 pmRNSCorrection of Dividend Declaration
28th Feb 20201:58 pmRNSTotal Voting Rights and Capital
28th Feb 20207:00 amRNSFiling of Annual Report on Form 20-F with US SEC
27th Feb 20209:55 amRNSBlock Listing Cancellation
24th Feb 202012:40 pmRNSDividend Declaration
20th Feb 20204:10 pmRNSHolding(s) in Company
14th Feb 20203:58 pmRNSRBSG ENTM Publication of Suppl.Prospcts
14th Feb 20207:01 amRNSAnnual Financial Report
14th Feb 20207:00 amRNSFinal Results
31st Jan 20202:12 pmRNSTotal Voting Rights and Capital
30th Jan 20203:57 pmRNSDirector/PDMR Shareholding
16th Jan 20202:08 pmRNSForm 8.3 - Accesso Technology Group plc
2nd Jan 20201:58 pmRNSForm 8.3 - Accesso Technology Group plc
31st Dec 20191:10 pmRNSDirector/PDMR Shareholding
31st Dec 201911:20 amRNSTotal Voting Rights and Capital
30th Dec 20193:02 pmRNSForm 8.3 - Accesso Technology Group plc
20th Dec 20197:00 amRNSPublication of Suppl.Prospcts replacement
19th Dec 20195:40 pmRNSPublication of Suppl.Prospcts
19th Dec 20197:00 amRNSNatWest Markets Change in Executive Directors
16th Dec 20195:47 pmRNS2019 Bank of England stress test results
4th Dec 201912:34 pmRNSForm 8.3 - Accesso Technology Group plc
2nd Dec 20195:34 pmRNSPublication of Suppl.Prospcts
29th Nov 20192:20 pmRNSDirector/PDMR Shareholding
29th Nov 20191:28 pmRNSAnnouncement of NatWest Markets N.V. Transfer
29th Nov 201912:01 pmRNSTotal Voting Rights and Capital
27th Nov 201911:56 amRNSDividend Declaration
21st Nov 20196:26 pmRNSPublication of a Prospectus
21st Nov 201910:45 amRNSReduction in Pillar 2A capital requirements
14th Nov 201911:23 amRNSPublication of Final Terms
13th Nov 20193:00 pmRNSForm 8.3 - Accesso Technology Group plc
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
1st Nov 20194:12 pmRNSDirector/PDMR Shareholding
31st Oct 20193:30 pmRNSDirector/PDMR Shareholding
31st Oct 20192:08 pmRNSTotal Voting Rights and Capital
30th Oct 20199:38 amRNSRBSG pricing of US$750mn of Subordinated Notes
25th Oct 20195:22 pmRNSPublication of Suppl.Prospcts
24th Oct 20197:00 amRNSQ3 Interim Management Statement
16th Oct 20192:54 pmRNSForm 8.3 - Accesso Technology Group plc
8th Oct 201911:35 amRNSBlock Listing Six Monthly Return
3rd Oct 20191:08 pmRNSPublication of Final Terms
1st Oct 20195:29 pmRNSDirector/PDMR Shareholding
30th Sep 20193:28 pmRNSTotal Voting Rights
24th Sep 20198:30 amRNSBank of America Merrill Lynch Annual Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.